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a b s t r a c t
Background: Few studies of the natural history of DSM-IV inhalant substance use disorders (I-SUDs) have
been conducted. This investigation examined the prevalence, timing, and predictors of transitions from
inhalant use to formal I-SUDs among inhalant users within a nationally representative sample.
Methods: Participants were 664 U.S. residents participating in the 2000–2001 National Epidemiologic
Survey on Alcohol and Related Conditions who reported lifetime inhalant use. Respondents completed
structured interviews assessing DSM-IV psychiatric/substance use disorders. Bivariate and Cox regression
analyses were conducted to identify risk factors for transitions from inhalant use to I-SUDs.
Results: Nearly one in five (19.4%) persons initiating inhalant use developed an I-SUD. Most I-SUD tran-
sitions were to inhalant abuse rather than inhalant dependence. Risk for development of I-SUDs was
greatest in the first year following initiation of inhalant use and low thereafter. Multivariate proportional
hazards models indicated that presence of a mood/anxiety disorder (HR = 7.7, CI = 3.1–18.9) or alcohol use
disorder (HR = 11.9, CI = 5.46–26.00) antedating initiation of inhalant use predicted significantly elevated
risk for I-SUDs, whereas being married conferred a lower risk for onset of I-SUDs.
Conclusions: I-SUDs were relatively common among inhalant users, generally occurred in the year fol-
lowing initiation of inhalant use, and were associated with early-onset mood/anxiety and alcohol use
disorders. Given the young average age at onset of inhalant use and the rapidity with which most I-SUDs
developed, interventions directed to adolescents who have initiated inhalant use might be effective in
reducing the proportion of inhalant users who develop I-SUDs.
© 2008 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
Long neglected in the substance abuse research and clini-
cal literatures, inhalant use has been the focus of comparatively
intensive investigation in recent years (Medina-Mora and Real,
2008; Ridenour, 2005). National surveys in the U.S. indicate
that purposive inhalation of volatile solvents by the citizenry
may be more prevalent than generally recognized. For exam-
ple, Wu and Ringwalt (2006) reported that approximately 10.0%
of the 73,396 adults participating in the 2002–2003 National
Surveys on Drug Use and Health had used inhalants. Mon-
itoring the Future findings indicated that 15.6% of U.S. 8th
graders in 2007 had tried inhalants (Johnston et al., 2008).
Lifetime inhalant use is even more pervasive in many clinical
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(Compton et al., 1994; Sakai et al., 2004) and criminological
(Howard and Perron, 2008; McGarvey et al., 1999) client sam-
ples.
Inhalant use generally has been thought to have an early onset
and high discontinuation rate (Crocetti, 2008; D’Abbs and MacLean,
2008). Combined data from the 2002 to 2006 administrations of
the National Survey on Drug Use and Health indicated that past-year
inhalant use was reported by 3.4% and 4.8% of U.S. 12- and 13-
year-olds, 5.3% and 5.1% of 14- and 15-year-olds, and 4.2% and 3.9%
of 16- and 17-year-olds (SAMHSA, 2008). Thus, although annual
prevalence rates were similar for the period spanning early-to-late
adolescence, the highest prevalence rate for past-year inhalant use
was observed among 14-year-olds. Similarly, Siqueira and Crandall
(2006) found that lifetime inhalant use was most prevalent among
14-year-olds in their survey of 60,345 Floridian students in 6th to
12th grade.
Widespread inhalant use, though underappreciated, is a serious
public health concern. Even a single episode of inhalant use can
result in “sudden sniffing death” (Alper et al., 2008; Pfeiffer et al.,
0376-8716/$ – see front matter © 2008 Elsevier Ireland Ltd. All rights reserved.
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2006). Many inhalants, such as gasoline, glue, and paint thinner are
neurotoxic and capable of producing diffuse white matter changes
associated with significant functional deficits (Finch and Lobo,
2005; Lubman et al., 2008). Reports of inhalant-related kidney,
heart, and nerve damage are available in the scientific literature
(e.g., Gautschi et al., 2007; Weintraub et al., 2000). Given the
disproportionately scant empirical attention that inhalants receive
in the broader substance abuse literature, Balster’s recognition that
inhalants are a “silent epidemic” still hold true today (Balster, 1997).
Widely used and medically consequential, inhalant use is also
associated with a broad range of psychiatric comorbidities, sub-
stance use disorders, and adverse life circumstances. Ethnographic,
national, and local survey studies suggest that inhalant users are
found disproportionately among persons with poor school perfor-
mance; the poor and otherwise socially marginalized; polydrug and
IV-drug users; the mentally ill; youth with dysfunctional family
backgrounds including parental alcoholism and criminality, poor
or absent parenting, and histories of physical or sexual abuse;
youth with deviant peer role models including friends who use
inhalants; and persons with neuropsychological and learning dis-
orders (D’Abbs and MacLean, 2008; Dinwiddie, 1998; Lubman et
al., 2008). Inhalants are most apt to be abused by geographically
and/or socially isolated persons who, by virtue of age, distance, or
impoverishment, do not have access to other psychoactive agents
(Dinwiddie, 1994; Oetting et al., 1988; Williams and Storck, 2007).
The majority of research on inhalant use has relied on sur-
vey methods. Although relatively few ethnographic studies have
examined inhalant use, Seth et al. (2005) conducted one such inves-
tigation with 45 street children in Delhi, noting the key role played
by inhalant-using peers in promoting onset of inhalant use, the
low cost and ready availability of the toluene solution that was
inhaled, and the occasional occurrence of inhalant-related with-
drawal symptoms and overdose. Among the reported reasons for
inhalant use were to cope with sadness, anger, and other nega-
tive emotional states, because it is pleasurable, and to cope with
unpleasant work circumstances. Similar findings were reported
in an ethnographic study of 31 Australian Aboriginal youth, who
reported boredom and pleasure as among their chief reasons for
inhalant use. Members of the local community regarded inhalant
users as “scary,” unpredictable, and social disenfranchised (Senior
et al., 2006; see also MacLean, 2005, 2007).
In the only studies published to date of inhalant users partici-
pating in the National Epidemiologic Survey on Alcohol and Related
Conditions (NESARC), the largest nationally representative comor-
bidity survey ever conducted in the U.S., Wu et al. (2008) reported
that approximately 2% of NESARC respondents had a lifetime his-
tory of inhalant use, and approximately one-in-five inhalant users
(19%) had a lifetime inhalant use disorder. Among respondents with
a lifetime history of inhalant use, 62% had a past-year and 96%
had a lifetime DSM-IV substance use disorder. Psychiatric disorders
were also prevalent among this sample of inhalant users. Nearly
three-quarters (70%) of inhalant users met criteria for one or more
lifetime mood, anxiety, or personality disorders and 38% had expe-
rienced a mood or anxiety disorder within the prior year (Wu and
Howard, 2007). Other reports document high rates of suicidality
(Freedenthal et al., 2007; Howard et al., 2008b), antisocial behavior
(Compton et al., 2005; Howard et al., 2008c), substance use (Wu et
al., 2008), and disadvantaged family and social life circumstances
(Sakai et al., 2004) among inhalant users.
Research to date has focused largely on inhalant use rather than
formal inhalant substance use disorders (I-SUDs). Little is known
about the natural history of I-SUDs, particularly regarding factors
that promote transitions from inhalant use to inhalant abuse and
dependence. At present, there is no consensus as to the abuse liabil-
ity of inhalants (i.e., proportion of inhalant users who progress to
I-SUDs). Anthony et al. (1994) reported that only 3.7% of lifetime
inhalant users participating in the National Comorbidity Survey
met criteria for inhalant dependence. Sakai et al. (2004) found that
although 18.0% of a clinical sample of adolescents (N = 847) had used
inhalants, only 3.3% met DSM-IV inhalant abuse or dependence cri-
teria. High rates of abuse liability (40–50%) were reported, however,
by Howard and Perron (2008) and Ridenour et al. (2007) for samples
of antisocial adolescents and community-residing inhalant users,
respectively.
Whereas only limited and conflicting data are available regard-
ing the abuse liability of inhalants, virtually no data (of which we are
aware) are available identifying factors that predict the occurrence
and timing of transitions from inhalant use to I-SUDs. To address
these gaps in the literature, we utilized NESARC data to (1) eval-
uate the proportion and characteristics of lifetime inhalant users
who progressed to I-SUDs and (2) identify factors predictive of the
occurrence and timing of transitions from inhalant use to I-SUDs.
Findings of this study may lead to better understanding of the natu-
ral history of I-SUDs and provide an empirical foundation for future
I-SUD treatment and prevention interventions.
2. Methods
2.1. Subjects, sampling, and interviews
This study used data from the 2001 to 2002 NESARC, a representative sample of
43,093 U.S. adults (Grant et al., 2003), which gathered information on substance use
and comorbid conditions from individuals living in households and group settings.
NESARC utilized a multistage sampling design and had an overall response rate of
81%. Data were weighted at the individual and household levels and adjusted for
oversampling, nonresponse, and to be representative of the U.S. population vis-à-vis
the 2000 census.
U.S. Census Bureau workers administered the alcohol use disorders and
Associated Disabilities Interview Schedule (AUDADIS-IV), a structured interview
designed for administration by lay interviewers. AUDADIS-IV assesses DSM-IV sub-
stance use disorders with good reliability (Grant et al., 1995, 2003). The NESARC
survey, sampling protocol, related publications, and codebook are available at
http://www.nesarc.niaaa.nih.gov/.
2.2. Measurement
2.2.1. Inhalant use and I-SUDs
Participants included lifetime inhalant nonusers and inhalant users. Inhalant
users answered affirmatively to the question, “Have you ever used inhalants or
solvents, for example, amyl nitrite, nitrous oxide, glue, toluene, or gasoline?” An
introductory statement preceding the inhalant question informed respondents that
they were to report inhalants used on their own, without a doctor’s prescription,
and for the purposes of getting high, enjoying themselves, relaxing, feeling better,
feeling more alert, quieting their nerves, or to see how they would work. Inhalant
abuse diagnoses were assigned to inhalant users who met DSM-IV inhalant abuse
criteria but who did not meet inhalant dependence criteria; inhalant dependence
diagnoses were assigned to subjects who met DSM-IV inhalant dependence criteria
(American Psychiatric Association, 2000).
2.2.2. Transitions from inhalant use to I-SUD
The primary outcome in this study was the transition from inhalant use to a
DSM-IV I-SUD (abuse or dependence). In bivariate analyses, this outcome was spec-
ified as a dichotomous variable, reflecting whether inhalant use developed into an
I-SUD. In survival analyses (see analytic plan), the transition from inhalant use to an
I-SUD was modeled as a time-to-event measure, capturing both the occurrence and
timing of transitions from inhalant use to I-SUDs. The time-to-event was defined as
the amount of time (in years) that elapsed between age at onset of inhalant use to the
age at which I-SUD criteria were first met. Inhalant users who had not transitioned
to I-SUDs at the time of the study were treated as right-censored observations, with
the censoring time based on the difference between age at the time of NESARC
interview and age at first inhalant use.
2.2.3. Covariates
Age at onset of inhalant use referred to the respondents’ age at the time they
first used inhalants. Lifetime DSM-IV drug use disorders included abuse or depen-
dence on heroin, hallucinogens, cocaine/crack, marijuana, stimulants, painkillers,
tranquilizers, and sedatives. Lifetime psychiatric disorder included diagnosis with a
mood (depression, dysthymia, mania, and hypomania) or anxiety (social phobia, spe-
cific phobia, agoraphobia, panic, and generalized anxiety disorder) disorder. Lifetime
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DSM-IV alcohol use disorders included alcohol abuse or dependence. The AUDADIS-
IV established the age of onset for substance use and psychiatric disorders, which
were used to specify whether or not they preceded onset of inhalant use. Lifetime
DSM-IV conduct disorder and antisocial personality disorder were also included in
this study. However, the AUDADIS-IV does not establish a time of onset for these
disorders, so it was not possible to define whether or not they preceded inhalant
use.
Response categories for region of residence in the U.S., race, gender, age, annual
family income, and marital, educational, and unemployment status are listed in
Table 1. Family histories of alcohol, drug, and antisocial behavior problems, respec-
tively, were recorded as present/absent based on respondents’ reports as to whether
their biological parents (father and/or mother) had ever “been an alcoholic or prob-
lem drinker,” had “problems with drugs,” or had “behavior problems.”
2.3. Analytic plan
Differences between inhalant users with and without I-SUDs were examined
using chi-square (!2) tests for categorical variables and t-tests for continuous vari-
ables. Kaplan–Meier (K–M) estimates were computed to represent the unadjusted
probability of surviving to each time point without transitioning to an I-SUD. These
estimates are represented graphically in survival curves. Separate K–M estimates
were computed for categorical variables, and a log-rank test was used to test group
differences.
Cox proportional hazards regression analysis was used to examine factors asso-
ciated with time-to-an-I-SUD following onset of inhalant use. Hazard ratios were
derived to reflect the association between each variable and risk of transitioning
to an I-SUD. Hazard ratios that did not include the value 1.00 in 95% confidence
intervals were statistically significant.
Analyses were conducted using SUDAAN v. 9.0 (Research Triangle Institute,
2004). SUDAAN implements a Taylor series linearization to adjust standard errors
of estimates for complex survey sampling design effects involving clustered data.
SUDAAN does not provide the log-rank test for comparing group differences in K–M
survival estimates. Therefore, results produced by SUDAAN were compared with
those produced by PROC LIFETEST using SAS. The results and standard errors pro-
duced by SAS and SUDAAN were nearly identical. Therefore, PROC LIFETEST was
used to test for group differences.
3. Results
3.1. Characteristics of inhalant users
Approximately 74.2% of lifetime inhalant users were male and
82.2% were White (Table 1). The majority was unmarried and a
substantial minority had a high school education or less. Only
a small percentage of inhalant users had a DSM-IV drug use or
alcohol use disorder that preceded inhalant use (7.8% and 9.8%).
Approximately one in eleven (9.3%) inhalant users had developed
a DSM-IV mood and/or anxiety disorder prior to initiating inhalant
use. Approximately one-third of the sample met criteria for con-
duct disorder or antisocial personality, and these disorders were not
limited to those that preceded inhalant use onset. Approximately
22.2% had a family history of behavior problems, and 50.5% had a
family history of substance use disorders. The mean age of onset
of inhalant use was 17.5 years (95% CI = 16.0–17.9), with a range
of 5–44.
Table 1
Socio-demographic and clinical characteristics of inhalant users with and without DSM-IV Inhalant Use Disorders.




(N = 138) % (S.E.)
Without an I-SUD
(N = 526) % (S.E.)
Chi-square (p)
Sex .68 (.414)
Male 74.2 (2.02) 77.7 (4.19) 73.3 (2.48)
Female 25.8 (2.02) 22.4 (4.19) 26.7 (2.48)
Annual family income past 12 months 1.62 (.656)
<$19,999 28.4 (2.21) 33.1 (5.3) 27.2 (2.30)
$20,000–34,999 18.9 (1.64) 19.5 (3.69) 18.8 (1.89)
$35,000–69,999 31.8 (2.15) 30.1 (5.42) 32.2 (2.42)
$70,000+ 20.9 (2.01) 17.4 (4.27) 21.8 (2.20)
Region of United States 3.99 (.273)
Northeast 21.7 (4.02) 17.8 (4.65) 22.6 (4.23)
Midwest 21.6 (3.41) 22.5 (5.79) 21.3 (3.63)
South 25.4 (3.28) 33.6 (6.01) 23.4 (3.36)
West 31.4 (4.10) 26.1 (5.81) 32.7 (4.28)
Education 5.50 (.071)
Less than high school 13.8 (1.65) 20.6 (4.23) 12.2 (1.76)
High school 27.2 (2.39) 30.4 (4.65) 26.4 (2.58)
More than high school 59.0 (2.59) 49.0 (5.05) 61.5 (2.79)
Marital status .95 (.623)
Married 43.7 (2.30) 39.8 (4.51) 44.6 (2.61)
Separated/widowed/divorced 17.4 (1.73) 17.8 (3.12) 17.3 (2.08)
Never married 39.0 (2.26) 42.5 (4.50) 38.1 (2.55)
Race .62 (.434)
White 82.2 (1.74) 79.6 (3.76) 82.9 (1.97)
Non-White 17.8 (1.74) 20.4 (3.76) 17.1 (1.97)
Age of inhalant onset, mean (S.E.) 17.5 (.22) 16.0 (.38) 17.9 (.26) 16.31 (<.001)a
Age of inhalant onset, median (S.E.) 16.2 (.20) 15.1 (.31) 16.5 (.22) NA
Established DSM-IV drug use disorder prior to onset of inhalant useb 7.8 (1.48) 38.8 (5.70) 0.3 (.32) 26.30 (<.001)
Established DSM-IV alcohol use disorder prior to onset of inhalant use 9.8 (1.4) 49.0 (5.41) 0.5 (.35) 42.3 (<.001)
DSM-IV antisocial personality or conduct disorder 33.9 (.52) 46.8 (5.07) 30.8 (2.49) 7.52 (.008)
Established DSM-IV mood and/or anxiety disorder prior to onset of inhalant use 9.3 (1.30) 43.8 (4.61) 1.0 (.49) 38.38 (<.001)
Family history of antisocial behavior problems 22.2 (1.90) 24.2 (4.49) 21.8 (2.14) .23 (.633)
Family history of substance use disorders 50.5 (2.31) 60.4 (5.17) 48.1 (2.59) 4.35 (.041)
Note: Values in bold are statistically significant (p < .05); NA = not available.
a F-value.
b Abuse of or dependence on heroin, hallucinogens, cocaine/crack, marijuana, stimulants, painkillers, tranquilizers, and sedatives.
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3.2. Bivariate associations with I-SUDs
Overall, approximately 19.4% (N = 138) of inhalant users transi-
tioned from inhalant use to an I-SUD. Seventeen percent of inhalant
users 17% (N = 117) met criteria for inhalant abuse, and 2.3% (N = 21)
met criteria for dependence. Given the small sample of persons
with inhalant dependence, inhalant abuse and dependence were
combined for subsequent analyses involving I-SUDs.
No sociodemographic factors were significantly associated with
transitions from inhalant use to an I-SUD. With the exception of
family history of antisocial behavior, all clinical variables were pre-
dictive of elevated risks for development of I-SUDs. Specifically,
among persons who transitioned from inhalant use to an I-SUD,
38.8% had a substance use disorder prior to initiating inhalant use,
compared with only .3% of inhalant users who did not develop an I-
SUD. A similar pattern was observed for preexisting mood/anxiety
disorders (43.8% transitioning to I-SUDs vs. 1.0%). Inhalant users
who transitioned to an I-SUD were also more likely to have a his-
tory of a DSM-IV conduct disorder and/or antisocial personality
disorder (46.8% vs. 30.8%) and family history of substance use dis-
orders (24.2% vs. 21.8%) compared with inhalant users who did not
develop I-SUDs. Inhalant users who transitioned to an I-SUD were
more likely to have an earlier mean age of inhalant use onset (16.0
years vs. 17.9 years).
3.3. Transitions from inhalant use to an I-SUD
The survival analysis was based on 97.6% of inhalant users
(N = 648), as 2.4% of inhalant users with an I-SUD had miss-
ing values for their age of onset of an I-SUD. The mean age of
onset for inhalant abuse was 17.0 (95% CI = 15.9–18.1; range = 6–53;
N = 103); for inhalant dependence, it was 16.8 (95% CI = 14.8–18.9;
range = 9–31; N = 19). Table 2 provides a summary of estimated sur-
vival probabilities for these inhalant users. These values represent
the probability of surviving to that point in time (measured in years)
without transitioning to an I-SUD (abuse or dependence). Thus,
at 1 year following inhalant use onset, approximately 86% (95%
CI = .82–.89) of inhalant users had not developed an I-SUD. The
greatest risk of transitioning to an I-SUD occurred during the first
year following initiation of use and was consistently low thereafter.
It should be noted that the discrepancy between the proportion
of subjects who transitioned to an I-SUD and the estimated sur-
vival probability is due to censoring of observations and missing
data.
Fig. 1a–f provides a graphical representation of K–M survival
probabilities for the first 10 years following initiation of inhalant
use, stratified by each clinical variable that was statistically signif-
icant. These unadjusted curves were statistically significant based
on a likelihood ratio test (p < .001).
Table 2
Kaplan–Meier probabilities of not progressing to a DSM-IV Inhalant Use Disorder






1 .86 (.02) .82–.89
2 .84 (.02) .79–.87
3 .83 (.02) .78–.86
4 .82 (.02) .78–.85
6 .82 (.02) .78–.85
9 .81 (.02) .77–.85
11 .81 (.02) .77–.84
13 .81 (.02) .76–.84
19 .80 (.02) .76–.84
39 .77 (.04) .67–.84
Note: S.E. = standard error; CI = 95% confidence interval.
Table 3
Socio-demographic and clinical variables associated with onset of an Inhalant Use
Disorder following first inhalant use based on Cox regression analysis.
















Less than high school 1.28 .67–2.44
High school .90 .50–1.61








DSM-IV drug use disorder preceded inhalant use
Yes 2.03 .93–4.42
No Ref –
DSM-IV alcohol use disorder preceded inhalant use
Yes 11.92 5.46–26.00
No Ref –
DSM-IV antisocial personality disorder or conduct disorder
Yes 1.31 .77–2.23
No Ref –
DSM-IV mood and/or anxiety disorder preceded onset of inhalant use
Yes 7.67 3.11–18.86
No Ref –
Age of inhalant onset, mean (S.D.) .78 .73–.83
Family history of behavior problems
Yes .96 .55–1.70
No Ref –
Family history of SUD
Yes 1.08 .68–1.72
No Ref –
Note: Ref = reference group. Values in bold are statistically significant, based on a
95% confidence interval that does not include the value 1.00.
3.4. Factors associated with transitions to an Inhalant Use
Disorder
Table 3 presents hazard ratios (HR) derived from a Cox regres-
sion analysis. Being married was associated with a significantly
lower risk of transition to an I-SUD (HR = .61, 95% CI = .38–.96). Liv-
ing in the South was also associated with twice the likelihood
of transitioning compared with inhalant users living in the West
(HR = 2.18, 95% CI = 1.18–4.00). Conduct disorder and/or antisocial
personality disorder and family history of behavior problems were
statistically significant in the unadjusted survival estimates, but
were no longer significant after controlling for other factors. Having
an earlier age at onset of inhalant use was associated with a sig-
nificant increase in the risk of developing an I-SUD (HR = .78, 95%
CI = .73–.83). Comorbid DSM-IV mood/anxiety and alcohol use dis-
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Fig. 1. Kaplan–Meier survival curves representing probabilities of not progressing to a DSM-IV Inhalant Use Disorder over 10 years following initiation of inhalant use. Note:
AUD = alcohol use disorder (abuse or dependence). SUD = non-inhalant and non-nicotine DSM-IV substance use disorder (abuse or dependence). ASPD = antisocial personality
disorder. SUD = non-inhalant and non-nicotine substance use disorder. Variables used for stratifying curves 1a–e are statistically significantly (p < .001) based on a likelihood
ratio test.
orders preceding onset of inhalant use were significant risk factors
for I-SUDs. Specifically, inhalant users who had developed a mood
or anxiety disorder prior to initiating inhalant use were at 7.67
times the risk of transitioning to a I-SUD compared with inhalant
users free of comorbid anxiety and/or mood disorders, and inhalant
users with an established alcohol use disorder prior to onset of
inhalant use were at nearly eight times the risk (HR = 7.67, 95%
CI = 3.11–18.86).
4. Discussion
4.1. Prevalence, timing, and predictors of I-SUDs
4.1.1. Abuse liability of inhalants. I-SUDs were common among
lifetime inhalant users; nearly one in five such users developed
an I-SUD. Inhalant users who developed I-SUDs typically evi-
denced a rapidly progressive and clinically significant pattern of
inhalant use, such that they met DSM-IV inhalant abuse crite-
ria within 12 months of initiating inhalant use. Inhalant abuse is
defined by the presence of one or more of the following signs:
a pattern of recurrent inhalant use in situations in which it is
physically hazardous, recurrent inhalant-related legal problems,
continued inhalant use despite having persistent or recurrent
social or interpersonal problems caused or exacerbated by the
effects of inhalants, and recurrent inhalant use resulting in a
failure to fulfill major role obligations at work, home, or school
(American Psychiatric Association, 2000). Study findings with
regard to the abuse liability of inhalants accord reasonably well
with the results of Ridenour et al. (2007), who reported that 27.9%
of 162 community-based inhalant users met inhalant abuse crite-
ria, and with Howard and Perron’s (2008) observation that 22.2%
of 279 delinquent inhalant users met criteria for inhalant abuse.
However, Ridenour et al. (2007) and Howard and Perron (2008)
reported substantially higher rates of inhalant dependence among
lifetime inhalant users than were observed in the present study, a
difference potentially attributable to sociodemographic and clini-
cally relevant variations in the composition of the samples studied
and to the diverse assessment and diagnostic methods employed.
Anthony et al. (1994) noted that only 3.7% of lifetime inhalant users
participating in the National Comorbidity Survey (NCS) met criteria
for inhalant dependence, but did not report prevalence figures for
inhalant abuse. It is, therefore, unknown to what extent NCS and
NESARC findings for prevalence of inhalant abuse among lifetime
inhalant users converge, although risk for inhalant dependence
was low in both national surveys. Additional research is needed
to establish the abuse liability of inhalants in different respon-
dent populations and for different clinical outcomes (e.g., abuse vs.
dependence).
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In the current study, the abuse liability of inhalants was lower
in comparison to other drugs. For example, a posterori analyses of
NESARC data show that the overall rates of lifetime disorders (i.e.,
abuse or dependence) for lifetime opioid, cannabis, and cocaine
users were 30%, 41%, and 46%, respectively. It is important to note
that the overall abuse liability of inhalants remains unclear, given
the measurement limitations of NESARC. Specifically, hundreds of
household products could be used to get high, but inhalant use was
measured with a single omniibus question. Thus, the abuse liability
for many specific inhalants could not be computed and compared.
Future research on inhalant use would benefit from detailed exam-
inations of the types, amounts, and modes of use.
4.1.2. Timing of transitions from inhalant use to I-SUDs. As noted
above, most transitions to I-SUDs occurred in the year following
onset of inhalant use and, given the comparatively early average
age at onset of inhalant use, generally occurred among older adoles-
cents and young adults. Together with other studies documenting
early onset of inhalant use (Bennett et al., 2000; Prinz and Kerns,
2003; Storr et al., 2005), results of the current investigation suggest
that inhalant prevention and treatment interventions will need to
target youth early in life, particularly those who have recently ini-
tiated inhalant use and who otherwise present a high-risk profile
for eventual progression to I-SUDs.
The average age of onset of inhalant use in this study was 17.5,
significantly older than the mean ages of onset (i.e., 14–15) reported
in other clinical, criminological, and general population samples of
youth (e.g., Johnston et al., 2008; McGarvey et al., 1999; Siqueira
and Crandall, 2006). The median age of inhalant use onset in this
study was 16.2, suggesting that the age of inhalant onset distribu-
tion was positively skewed and that a relatively small percentage
of reports of inhalant use onset later in life could have signifi-
cantly influenced the estimated overall mean age of inhalant use
onset. Johnson and Schultz (2006) noted that retrospective reports
of onset in surveys are subject to forward telescoping, a tendency
on the part of respondents to report the occurrence of onset closer
to the time of interviewing than is accurate. Thus, it is possible that
a forward telescoping bias on the part of inhalant users who were
older, may have contributed to the right skewing of the age of onset
distribution and to the finding, for this sample, of a comparatively
older age of onset than is typically reported.
4.1.3. Predictors of inhalant use to I-SUD transitions. Established
mood, anxiety, and substance use disorders, many of them early-
onset in nature, were potent predictors of inhalant users’ transitions
to I-SUDs, a novel finding that extends results of recent reports
(Howard et al., 2008a,b,c; Wu and Howard, 2007; Wu et al., 2008)
identifying high rates of substance use and psychiatric disorders
among lifetime inhalant users. Study findings are compatible with
self-medication theories of inhalant use and with “third factor”
accounts identifying social and biological precursors to inhalant
use and other drug use and psychiatric disorders.
4.2. Study limitations
The findings of this study should be considered in context of
its limitations. The target population for the survey was adult,
noninstitutionalized, U.S. civilians; thus, military personnel, per-
sons younger than 18, and residents of jails, prisons, mental health
institutions, and persons living on the streets with no permanent
address were not included in the survey. Findings were based
on participants’ self-reports and consequently subject to typical
limitations of self-report data, including respondents’ unreliable
retrospective recall, failure to report socially stigmatized behaviors
such as drug use (i.e., social desirability bias), and decreasing abil-
ity to access information needed to accurately answer questions
over time (i.e., transience). Retrospective reports of inhalant use
onset and onset of I-SUDs by persons of widely differing ages may
have influenced estimation of the interval between these events in
ways that are difficult to assess. It is also conceivable that use of
a single ombinus inhalant assessment question may have under-
estimated the actual level of inhalant use in a given population
(e.g., Howard et al., 2008a,b,c), but there is no evidence that this
assessment approach (which is the current standard) leads to bias
in the ascertainment of inhalant-using respondents. NESARC is
a cross-sectional survey requiring respondents to report on the
nature and timing of various events and experiences in their lives at
one assessment point; thus, any reported associations must await
longitudinal investigation before any causal assertions can be con-
fidently assumed. For each of the statistically significant clinical
variables, confidence intervals were wide, suggesting some unrelia-
bility in the estimates. However, effect sizes for key variables at their
lower bounds, especially substance use and psychiatric disorders
that preceded inhalant use, were large.
4.3. Implications and future research
As noted above, study findings suggest that I-SUDs develop
relatively early in life and in a narrowly circumscribed period fol-
lowing initiation of inhalant use. Future research should examine
additional features of the natural history of inhalant use includ-
ing factors related to the onset of use, number and duration of
I-SUD episodes over the life course, remission from I-SUDs, and
eventual cessation of inhalant use and resolution of I-SUDs. The
role of genetic, temperamental, psychosocial, economic, and geo-
graphic factors in inhalant use onset, escalation, maintenance, and
cessation should be evaluated in carefully controlled longitudinal
studies with large samples and growth curve and other relevant
analytic methods. Ideally, it would be useful to assess the natural
history and consequences of inhalant use for individual inhalant
products of abuse, such as gasoline, given that the pharmacolog-
ical properties, modes of use, consequences, and other properties
of specific inhalant agents may vary significantly. Few prevention
and treatment approaches targeted to adolescent inhalant users
and youth at risk for initiating inhalant use have been developed or
evaluated. Funding these efforts should be a priority of the National
Institute on Drug Abuse and other national federal bodies, given the
widespread and potentially deleterious consequences of inhalant
use.
This study is the first (of which we are aware) to examine the
timing and predictors of transitions from inhalant use to Inhalant
Use Disorders using a survival analytic approach and a large sample
of inhalant users derived from a nationally representative survey.
Although longitudinal, prospective research is needed to clarify
the role that substance use and psychiatric disorders play in the
escalation of inhalant use following experimental use, our find-
ings indicate that youth who initiate inhalant use early in life and
who suffer from preexisting anxious-depressive disorders are at
significantly elevated risk for transitions from inhalant use to abuse
within the year they initiate inhalant use.
Cultural factors have received insufficient attention vis-à-vis
inhalant use and could not be examined in this study due to
availability of data. Prior research has found that greater west-
ernization among Zimbabwean youth (Eide and Acuda, 1997), and
greater acculturation among Hispanic youth in the U.S. (Ramirez
et al., 2004), predicted inhalant use, although it is unclear why
these factors were associated with increased inhalant use. Qual-
itative research, particularly ethnographic methods, can be useful
for expanding the knowledge base on the natural history of inhalant
use, abuse, and dependence, while offering a greater understanding
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to the role of cultural factors. Qualitative methods are also critical of
generating new hypotheses to inform the construction of hypothe-
ses that can be tested with survey methods. Further research is
needed to better understand how individuals are introduced to
inhalants and their reasons for use. For example, Perron et al. (2008)
identified three distinct subgroups of adolescent users based on
their reasons for use. These groups exhibited significant differ-
ences on a variety of clinical measures, including anxiety, problems
associated with using substances, global symptom severity, and
number of different types of inhalants used. This suggests that
factors motivating individuals to use inhalants are likely a key fac-
tor to consider in the future. Qualitative methods, combined with
long-term prospective studies of the natural history of inhalants are
needed to develop culturally responsive prevention and treatment
interventions related to inhalant use.
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